How many 8-K filings has Windtree Therapeutics Inc /De/ filed?

Windtree Therapeutics Inc /De/ (WINTW) has 50 8-K (Current Event Report) filings on record, spanning Apr 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Windtree Therapeutics Inc /De/ 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Windtree Therapeutics Inc /De/ 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Windtree Therapeutics Inc /De/ (WINTW) — 8-K Filings

All 8-K filings from Windtree Therapeutics Inc /De/. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

8-K Filing — Dec 2, 2025
Windtree Therapeutics Files 8-K on Financial Obligations & Equity Sales — Oct 16, 2025 Risk: medium
On October 9, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing the creation of a direct financial obligation and unregistered sales of equity sec
Windtree Therapeutics Files 8-K — Oct 6, 2025 Risk: low
On October 6, 2025, Windtree Therapeutics, Inc. filed an 8-K report to disclose a material definitive agreement and financial statements. The company, previousl
Windtree Therapeutics Appoints New CMO, Elects Director — Sep 8, 2025 Risk: medium
Windtree Therapeutics, Inc. announced on September 2, 2025, the appointment of Dr. Paul J. McNelis as Chief Medical Officer and the election of Ms. Sarah E. Kel
Windtree Therapeutics Files 8-K on Security Holder Vote Matters — Sep 2, 2025 Risk: medium
On August 28, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not specify
Windtree Therapeutics Faces Delisting Concerns — Aug 20, 2025 Risk: high
Windtree Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The com
Windtree Therapeutics Files 8-K — Aug 8, 2025 Risk: low
On August 4, 2025, Windtree Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is located at 2600 Kelly Road, Suite 100, Warrington,
Windtree Therapeutics Files 8-K — Aug 5, 2025 Risk: low
On August 5, 2025, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes fin
Windtree Therapeutics Appoints New Directors and Officers — Aug 4, 2025 Risk: medium
Windtree Therapeutics, Inc. announced on July 29, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new
Windtree Therapeutics Files 8-K with Material Agreements — Jul 24, 2025 Risk: medium
On July 23, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The company also reported
Windtree Therapeutics Files 8-K with Material Agreements — Jul 17, 2025 Risk: medium
On July 16, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities a
Windtree Therapeutics Enters Material Definitive Agreement — Jul 3, 2025 Risk: medium
On June 27, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, form
Windtree Therapeutics Announces Material Agreements & Officer Changes — Jun 27, 2025 Risk: medium
On June 24, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company also
Windtree Therapeutics Faces Delisting Concerns — Jun 20, 2025 Risk: high
Windtree Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the
Windtree Therapeutics Files 8-K on Financial Obligations & Equity Sales — Jun 11, 2025 Risk: medium
On June 5, 2025, Windtree Therapeutics, Inc. entered into a Material Definitive Agreement, likely related to its financial obligations. The company also reporte
Windtree Therapeutics Files 8-K on Financials and Listing Status — May 16, 2025 Risk: medium
Windtree Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting on its results of operations and financial condition. The filing also addresses a notice of
Windtree Therapeutics Files 8-K with Material Agreements — May 1, 2025 Risk: medium
On April 30, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement. The company also made material modifications to the rights of its s
Windtree Therapeutics Enters Material Agreement — Apr 30, 2025 Risk: medium
On April 29, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securitie
Windtree Therapeutics Announces Board and Executive Changes — Apr 18, 2025 Risk: medium
On April 17, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates
Windtree Therapeutics Files 8-K on Financials — Apr 15, 2025 Risk: low
Windtree Therapeutics, Inc. filed an 8-K on April 15, 2025, reporting on its results of operations and financial condition, as well as financial statements and
Windtree Therapeutics Enters Material Definitive Agreement — Apr 10, 2025 Risk: medium
On April 4, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known
Windtree Therapeutics Files 8-K: Material Agreement & Financials — Mar 24, 2025 Risk: medium
On March 18, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also made a Reg
Windtree Therapeutics Files 8-K on Security Holder Rights — Feb 18, 2025 Risk: medium
On February 14, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles
Windtree Therapeutics Files 8-K on Security Holder Vote Matters — Feb 3, 2025 Risk: low
On February 3, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated
Windtree Therapeutics Files 8-K on Agreements and Equity Sales — Jan 27, 2025 Risk: medium
On January 24, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing several events. The company entered into a material definitive agreement and also
Windtree Therapeutics Announces Board and Compensation Changes — Jan 13, 2025 Risk: medium
Windtree Therapeutics, Inc. announced on January 8, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
Windtree Therapeutics Files 8-K Report — Jan 8, 2025 Risk: low
On January 8, 2025, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
Windtree Therapeutics Faces Delisting Concerns — Dec 5, 2024 Risk: high
Windtree Therapeutics, Inc. filed an 8-K on December 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The filing indicat
Windtree Therapeutics Files 8-K — Dec 4, 2024 Risk: low
On December 4, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
Windtree Therapeutics Files 8-K on Financials and Delisting Concerns — Nov 27, 2024 Risk: high
Windtree Therapeutics, Inc. filed an 8-K on November 21, 2024, reporting on its financial condition and operations. The filing also addresses a notice of delist
Windtree Therapeutics Board Changes and Officer Compensation — Nov 14, 2024 Risk: medium
Windtree Therapeutics, Inc. announced on November 8, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new di
Windtree Therapeutics Files 8-K — Oct 28, 2024 Risk: low
On October 28, 2024, Windtree Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Discovery L
Windtree Therapeutics Files 8-K — Oct 4, 2024 Risk: low
On October 4, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine updat
Windtree Therapeutics Files 8-K — Oct 1, 2024 Risk: low
On October 1, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits.
Windtree Therapeutics Files 8-K — Sep 30, 2024 Risk: low
Windtree Therapeutics, Inc. filed an 8-K on September 30, 2024, reporting on other events and financial statements. The company, formerly known as Discovery Lab
Windtree Therapeutics Files 8-K — Sep 25, 2024 Risk: low
On September 25, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," in
Windtree Therapeutics Submits Matters to Security Holders — Sep 24, 2024 Risk: medium
On September 24, 2024, Windtree Therapeutics, Inc. filed an 8-K report to announce that it has submitted matters to a vote of its security holders. The filing d
Windtree Therapeutics to be Acquired by Cerus Corporation Affiliate — Sep 13, 2024 Risk: medium
Windtree Therapeutics, Inc. announced on September 13, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Cerus Corporation
Windtree Therapeutics Files 8-K on Financials — Aug 20, 2024 Risk: low
Windtree Therapeutics, Inc. filed an 8-K on August 20, 2024, reporting on its results of operations and financial condition, and including financial statements
Windtree Therapeutics Appoints New Chief Medical Officer — Aug 14, 2024 Risk: medium
Windtree Therapeutics, Inc. announced on August 13, 2024, the appointment of Dr. Paul J. Hastings as Chief Medical Officer. Dr. Hastings brings extensive experi
Windtree Therapeutics Files 8-K: Material Agreement & Equity Sales — Jul 29, 2024 Risk: medium
On July 26, 2024, Windtree Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement. The company also repor
Windtree Therapeutics Announces Material Agreements and Equity Changes — Jul 22, 2024 Risk: medium
On July 18, 2024, Windtree Therapeutics, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company also
Windtree Therapeutics Secures $30M Loan Facility — Jul 10, 2024 Risk: medium
On July 3, 2024, Windtree Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc. for a term loan facility of up to $30 millio
Windtree Therapeutics Files 8-K Report — Jul 3, 2024 Risk: low
On July 3, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a corporate action or event, with no specific
Windtree Therapeutics Files 8-K on Agreements and Equity Sales — Jul 1, 2024 Risk: medium
On June 25, 2024, Windtree Therapeutics, Inc. entered into a material definitive agreement related to its financial obligations. The company also reported on un
Windtree Therapeutics Files 8-K Report — Apr 23, 2024 Risk: low
On April 23, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements and exhibits. No specifi
Windtree Therapeutics Files 8-K on Security Holder Rights — Apr 19, 2024 Risk: medium
On April 19, 2024, Windtree Therapeutics, Inc. filed an 8-K to report material modifications to the rights of security holders and amendments to its articles of
Windtree Therapeutics Files 8-K Report — Apr 17, 2024 Risk: low
On April 17, 2024, Windtree Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Discovery Labo
Windtree Therapeutics Files 8-K on Security Holder Vote Matters — Apr 10, 2024 Risk: medium
On April 10, 2024, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known
Windtree Therapeutics Secures Series A Funding — Apr 8, 2024 Risk: medium
On April 2, 2024, Windtree Therapeutics Inc. entered into a material definitive agreement, specifically a Series A Preferred Stock Purchase Agreement, with an i

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX